| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Jun 10, 2021 |
Director
Trans History: 14
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 7,528 | -- | 7,528 |
| Jun 10, 2021 |
Director
Trans History: 8
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 7,528 | -- | 7,528 |
| Jan 22, 2021 |
Chief Financial Officer
Trans History: 14
|
Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 8,000 | $6.00 | 8,000 |
| Aug 23, 2018 |
Chief Scientific Officer
Trans History: 21
|
Chief Scientific Officer | Form 4 | Conversion of derivative security | 1,231 | -- | 8,585 |
| Oct 23, 2019 |
Director
Trans History: 14
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 9,500 | $0.01 | 9,500 |
| Aug 23, 2018 |
Director
Trans History: 14
|
Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 10,000 | $6.12 | 10,000 |
| Aug 23, 2018 |
Director
Trans History: 14
|
Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 10,000 | -- | 10,000 |
| Oct 01, 2018 |
Director
Trans History: 18
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,516 | -- | 10,516 |
| Oct 01, 2018 |
Director
Trans History: 2
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,516 | -- | 10,516 |
| Oct 01, 2018 |
Director
Trans History: 11
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,516 | -- | 10,516 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.